Wells Fargo & Company Issues Positive Forecast for Immunovant (NASDAQ:IMVT) Stock Price

Immunovant (NASDAQ:IMVT) had its price objective increased by stock analysts at Wells Fargo & Company from $45.00 to $47.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 31.96% from the stock’s current price.

A number of other analysts also recently issued reports on the company. Citigroup reaffirmed a “positive” rating on shares of Immunovant in a research note on Thursday, September 24th. HC Wainwright reissued a “buy” rating on shares of Immunovant in a research report on Thursday, September 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research report on Friday, October 2nd. UBS Group reissued a “buy” rating on shares of Immunovant in a report on Wednesday, September 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Immunovant in a report on Tuesday, August 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.30.

Immunovant Trading Up 1.3%

IMVT traded up $0.47 on Tuesday, hitting $35.62. 100,063 shares of the company’s stock were exchanged, compared to its average volume of 1,508,490. Immunovant has a fifty-two week low of $21.86 and a fifty-two week high of $45.42. The firm has a 50-day moving average price of $32.98 and a 200-day moving average price of $32.15. The stock has a market cap of $7.36 billion, a price-to-earnings ratio of -12.70 and a beta of 0.95.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.27. During the same period last year, the firm posted ($0.73) earnings per share. On average, equities analysts predict that Immunovant will post -2.96 EPS for the current year.

Insider Buying and Selling

In related news, CFO Tiago Girão sold 6,606 shares of the stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $28.50, for a total value of $188,271.00. Following the completion of the transaction, the chief financial officer directly owned 234,192 shares in the company, valued at approximately $6,674,472. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Jay Stout sold 3,809 shares of the firm’s stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total value of $122,116.54. Following the sale, the chief technology officer directly owned 201,532 shares of the company’s stock, valued at approximately $6,461,115.92. This trade represents a 1.85% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 24,430 shares of company stock valued at $787,852 in the last ninety days. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Immunovant

Several institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company purchased a new position in shares of Immunovant during the second quarter worth $1,871,000. Renaissance Technologies LLC purchased a new stake in Immunovant during the 1st quarter worth approximately $4,782,000. GSA Capital Partners LLP purchased a new stake in Immunovant during the 2nd quarter worth approximately $2,515,000. Man Group plc acquired a new stake in Immunovant during the 2nd quarter worth approximately $5,399,000. Finally, Squarepoint Ops LLC acquired a new stake in Immunovant during the 2nd quarter worth approximately $2,996,000. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Key Immunovant News

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: IMVT-1402 met the primary endpoint in a potentially registrational trial for difficult-to-treat rheumatoid arthritis: 92.5% of patients receiving the 600 mg dose achieved an ACR20 response at Week 28, versus 75.6% on placebo (p=0.0139). Exploratory ACR50 and ACR70 responses also reached 80.0% and 52.5%, respectively. Immunovant plans to discuss the next regulatory steps with the FDA later this year, making those discussions an important upcoming catalyst. Immunovant corporate updates and financial results
• Positive Sentiment: Immunovant reported a loss of $0.47 per share, narrower than analysts’ estimate of a $0.74 loss and the $0.73 loss a year earlier. The earnings beat may provide a modest positive alongside the clinical update. Second-quarter earnings results
• Negative Sentiment: The company said it is unlikely to advance IMVT-1402 in Sjögren’s disease beyond its ongoing, fully enrolled Phase 2 trial, citing the evolving landscape and recent data in the field. This narrows the drug’s potential development opportunities, though other clinical timelines remain on track. Immunovant corporate updates and financial results

About Immunovant

Immunovant, Inc is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies.

The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.